StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Moderna (MRNA) downside has played out, HSBC raises rating
November 3, 2023 9:49 AM
Moderna (NASDAQ: MRNA) was raised to Hold from Reduce at HSBC on Friday, with the firm raising the price target ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Hot List
Upgrades
Next Articles
Moderna (MRNA) PT Lowered to $75 at TD Cowen
November 3, 2023 8:08 AM
Moderna (MRNA) PT Lowered to $100 at Jefferies
November 3, 2023 7:45 AM
Moderna (MRNA) PT Lowered to $125 at RBC Capital
November 3, 2023 6:26 AM
Moderna (MRNA) PT Lowered to $231 at Goldman Sachs
November 3, 2023 6:01 AM
HSBC Upgrades Moderna (MRNA) to Hold
November 3, 2023 3:37 AM
Deutsche Bank Downgrades Moderna (MRNA) to Sell, 'further negative revenue revisions pressure'
November 2, 2023 8:43 AM
Moderna reins in 2023 COVID vaccine forecast, shares tumble
November 2, 2023 6:47 AM
Moderna (MRNA) Reports Wide Q3 Loss on $3.1B Charge, as Revenues Beat
November 2, 2023 6:36 AM
